Evidence map›Paper›PMID 32958674›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer.

Lin-Lu Tseng, Hsin-Hung Cheng, Ta-Sen Yeh, Shih-Chiang Huang, Ya-Yun Syu, Chih-Pin Chuu, Chiou-Hwa Yuh, Hsing-Jien Kung, Wen-Ching Wang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Discovery and structural studies of histone demethylases.Frontiers in epigenetics and epigenomics · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Lin-Lu TsengInstitute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 300, Taiwan.
Hsin-Hung ChengInstitute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 300, Taiwan.
Ta-Sen YehDepartment of Surgery, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Shih-Chiang HuangDepartment of Anatomic Pathology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Ya-Yun SyuInstitute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 300, Taiwan.
Chih-Pin ChuuInstitute of Cellular and System Medicine, National Health Research Institutes, Miaoli 350, Taiwan.
Chiou-Hwa YuhInstitute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli 350, Taiwan.
Hsing-Jien KungDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95616.
Wen-Ching WangInstitute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 300, Taiwan; wcwang@life.nthu.edu.tw.
National Tsing Hua University · TWChang Gung Memorial Hospital · TWNational Health Research Institutes · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted treatments for advanced gastric cancer (GC) are needed, particularly for HER2-negative GC, which represents the majority of cases (80 to 88%). In this study, in silico analyses of the lysine histone demethylases (KDMs) involved in diverse biological processes and diseases revealed that PHD finger protein 8 (PHF8, KDM7B) was significantly associated with poor clinical outcome in HER2-negative GC. The depletion of PHF8 significantly reduced cancer progression in GC cells and in mouse xenografts. PHF8 regulated genes involved in cell migration/motility based on a microarray analysis. Of note, PHF8 interacted with c-Jun on the promoter of

Indexed as

AnimalsCell Line, TumorCell MovementErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHistone DemethylasesHumansMiceProtein Kinase C-alphaProto-Oncogene Proteins pp60(c-src)PTEN PhosphohydrolaseStomach NeoplasmsTranscription FactorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHistone DemethylasesPHF8 protein, humanPHF8 protein, mousePRKCA protein, humanProtein Kinase C-alphaProto-Oncogene Proteins pp60(c-src)PTEN PhosphohydrolasePTEN protein, humanTranscription FactorsHER2-negative gastric cancerhistone lysine demethylasePHF8PKCαPTEN

Identifiers

PMID32958674
PMCPMC7547212
OpenAlexW3087320631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.